Angiogenesis inhibition, long studied in the treatment of malignancies, has begun to emerge as a potential therapeutic approach in managing inflammatory arthritis, particularly rheumatoid arthritis.

Cardiac problems associated with vascular endothelial growth factor inhibitors occur frequently in patients with cancer.

Figure 2: Trans-dominant inhibition of proangiogenic integrins ... play both positive and negative roles in different phases of angiogenesis and/or could act as balancers or integrators of ...

After decades of work, Dr. Folkman and his team are now watching as clinical trials begin with two recently discovered angiogenesis inhibitors, endostatin and angiostatin. In this interview ...

The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for ...

Bid HK, Phelps DA, Xiao L, Guttridge DC, Lin J, London C, Baker LH, Mo X, Houghton PJ. The Bromodomain BET inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Mol Cancer Ther.

Combination treatment with a PARP inhibitor and an anti-angiogenic agent did not improve PFS when compared to chemotherapy or a PARP inhibitor alone.